Efficacy Of Statins In Non-alcoholic Fatty Liver Disease(NAFLD):a Meta-analysis

Objective：To systematically evaluate the efficacy and adverse events of statins forthe treatment of non-alcoholic fatty liver disease(NAFLD).Methods： The Cochrane Library, PubMed, OVID and CNKI data-bases weresearched to identify randomized controlled trials (RCT) on non-alcoholic fatty liverdisease treated with statins. Meta-analysis was performed using the softwareRevMan5.2.Results：Four randomized control trials were included. The meta-analysis revealedthat,compared with controls,statins significantly reduced the level of total cholesterol，Triglycerides，serum alanine aminotransferase and aspartate aminotransferase, therewas statistically significant difference between the two groups. The WMD(weightedmean difference) and95%confidence interval were-1.31[-1.55,-1.07],-0.57[-0.98,-0.16],-8.39[-14.32,-2.46]，-11.97[-18.12,-5.81]. It can also improved the liverechopattern, the OR（odds ratio OR）and95%CI were4.10[2.50,6.71]. In addition,statins also reduced the level of low-density lipoprotein(LDL) cholesterol, but therewas no statistically significant difference between the two groups, WMD and95%CIwere-0.57[-1.45,0.31].Conclusion：According to this meta-analysis, statins may improve serum amino-transferase levels and ultrasound findings. However, there is no evidence to provethat it can improve liver pathology. Rigorously designed randomized double-blindcontrolled trials are necessary before we may suggest statins as an effective treatmentfor patients with NAFLD.